An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2021-08-12
Target enrollment:
Participant gender:
Summary
This study is an international, multi-center, open-label study designed to provide oral
treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have
completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety
of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.